Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.

Podcast: Doug Drysdale, CEO of Cybin, tells Scrip about the controversial history of psychedelics and their potential role in addressing mental health disorders. The CEO also weighs in on consolidation in the psychedelic sector, which is currently dominated by biotech, and claims big pharma can no longer sit on the sidelines.